Marijuana Stocks

Much like the U.S. legal status on marijuana, the verdict on marijuana stocks is still up in the air. While the bulls like to think that the marijuana industry is about to explode with their optimism over the pending decriminalization and legalization of marijuana, the bears view marijuana stocks as a very risky investment to the point that they may be scams. Marijuana Penny Stocks such as Cannabis Science Inc (CBIS) are risky due to fact that they are in a grey legal area. But as Canada’s nascent legal marijuana market blossoms, many pot stocks are worth adding to your portfolio.

Related to Marijuana Stocks:

As Canopy Growth Stock Stalls, Pot Investors Mull What Will Happen Next?

By Chris Lau, InvestorPlace Contributor
Canopy Growth faces plenty of tough problems ahead. So too, do its competitors. When will outsized growth return to CGC?

We’re One Step Closer to the Ultimate Catalyst for Cannabis Stocks

By InvestorPlace Research Staff
Even as stocks are under pressure, cannabis continues to proceed down the path toward full legalization. It is closer now than ever.

Here’s How to Trade Aphria Stock Without Getting Smoked

By Chris Tyler, InvestorPlace Contributor
If you’re looking for a cannabis standout off and on the price chart, Aphria stock is delivering in more than one way for investors.

Aphria Stock Has the Best Chances of Soaring High in the Pot Market

By Chris Lau, InvestorPlace Contributor
Aphria has a strong brand, independent management and plenty of cash on the books to fund its expansion. How will Aphria stock fare next?

The Manitoba Harvest Acquisition Saved Tilray Stock This Quarter

By Will Ashworth, InvestorPlace Contributor
Tilray’s acquisition of Manitoba Harvest should help Tilray stock. TLRY stock may perform better than other marijuana stocks.

5 Top Stock Trades for Monday: JD, JCP, FB, AMAT and ACB

By Bret Kenwell, InvestorPlace Contributor
Facebook, Applied Materials, Aurora Cannabis, J. C. Penney and JD.com were our top stock trades for Monday.

Investors Can Still Get High on American Marijuana Stocks

By InvestorPlace Staff
Tune into 'Moneyline' with Matt McCall for more on CRON stock, other cannabis plays and three under-the-radar stocks you should watch.

Will It Get Worse Before It Gets Better for Hexo Stock?

By Tezcan Gecgil, InvestorPlace Contributor
As HEXO stock has overpromised and underdelivered in recent months. the Hexo stock price has declined very rapidly.

‘Cannabis 2.0’ May Not Be Enough to Save Canopy Growth Stock

By Thomas Niel, InvestorPlace Contributor
"Cannabis 2.0" could be the catalyst to save CGC stock. But other factors remain at play. Tread carefully before buying Canopy Growth stock.

Why Aurora Cannabis Stock Isn’t Worth a Hit Before Earnings

By Chris Tyler, InvestorPlace Contributor
Don’t expect Aurora Cannabis to pull an ace from its sleeve when it reports earnings this evening. Here's why ACB stock should be avoided.

Q3 Numbers Show Why Cronos Stock May Not Rebound in the Short Term

By Luke Lango, InvestorPlace Senior Investment Analyst
CRON stock will head way higher in the long run. But, the long-term rebound won't start until today's weak profit trends improve.

Tilray Stock Has Fallen and Can’t Get Up

By Dana Blankenhorn, InvestorPlace Contributor
Tilray stock, along with the rest of the marijuana sector, have fallen out of favor and won't get back up. They need consistent profit.

Don’t Expect Much From Aurora Cannabis Stock’s Upcoming Report

By Mark R. Hake, CFA
ACB stock is set to fall much further. Aurora can't make money because of lower selling prices, overspending and its huge cash burn.

3 Pros, 3 Cons for New Age Beverages Stock

By Josh Enomoto, InvestorPlace Contributor
NBEV stock has the potential to dominate the CBD-infused beverages market. But legal and competitive problems shouldn’t be ignored.

What to Expect From Aurora Cannabis Stock Ahead of Earnings

By Marie Brodbeck, InvestorPlace Contributor
With much of its debt coming due in March, ACB stock will need to calm investors' worries about dilution on this quarter's earnings call.

Aphria Stock Will Reward Patient Investors

By Will Healy, InvestorPlace Contributor
Aphria stock has declined in recent months along with its peers, but an eventual recovery by APHA should reward patient investors.

Why I Changed My Mind About Canopy Growth Stock

By Jonathan Berr, InvestorPlace Contributor
Canopy Growth stock is one of the four big Canadian pot companies that will report results for the quarter ended Sept. 30 this week and Street expectations aren't optimistic.

With Huge Cash Burn, Canopy Growth Stock Is Set to Fall Further

By Mark R. Hake, CFA
With its huge cash burn, Canopy Growth stock is set for further downside. Short sellers are raising their bets on CGC.

High Hopes: Tilray Stock Needs a Miracle to Finish 2019 Strong

By Ian Bezek, InvestorPlace Contributor
Investors justifiably have low expectations for TLRY stock ahead of quarterly earnings. Here's the outlook for Tilray through the end of 2019.
Load More